M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy PharmaphorumNovo Nordisk has sold the rights to one of the flagship candidates in its now-defunct cell therapy unit to AI start-up Cellular Intelligence.NeuroscienceRead full story pharminent May 12, 2026 (Last updated: May 12, 2026) Pharmaphorum Novo Nordisk has sold the rights to one of the flagship candidates in its now-defunct cell therapy unit to AI start-up Cellular Intelligence. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Third Circuit Affirms Denial of Stelara Biosimilar InjunctionNext: Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
